CYT-108
phase 1drug program · high · Sat Jun 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate a recombinant protease inhibitor / engineered A2M biologic for mild to moderate primary osteoarthritis of the knee, with potential reduction in pain, stiffness, functional impairment, and cartilage degradation.
Two intra-articular CYT-108 injections delivered 12 weeks apart versus placebo, with symptom questionnaires through 26 weeks and blood biomarker analysis for cartilage degradation products.
Phase 1 clinical trial for mild to moderate primary knee osteoarthritis.
Preclinical rat ACLT osteoarthritis study reported that A2M-108 reduced inflammation markers and cartilage damage, with enhanced attenuation of cartilage degeneration compared with wild-type A2M and A2M-98.
FACT / Fibronectin-Aggrecan Complex Biomarker
exploratorybiomarker · high · Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Use fibronectin-aggrecan complex as a biomarker associated with cartilage degradation and inflammatory joint or spine disease, including prediction of response to procedures such as lumbar discectomy.
ELISA-based detection of fibronectin-aggrecan complex from intraoperative lavage or synovial/epidural samples, with correlation to clinical outcome measures.
Prospective lumbar discectomy cohort found FAC positivity associated with clinical improvement at 3 months.
In 75 lumbar discectomy patients, FAC positivity was associated with clinical improvement, with reported positive predictive value of 85% and ROC AUC of 0.66 overall; a hip arthroscopy cytokine study found no statistically significant association between measured cytokines including FAC and 2-year outcome scores.
A2M Variant Osteoarthritis Research Program
preclinicalresearch program · high · Sun Jan 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Assess whether engineered alpha-2-macroglobulin variants can attenuate cartilage degeneration and improve chondroprotection compared with wild-type A2M.
Bovine cartilage explant assays and rat anterior cruciate ligament transection osteoarthritis model treated with intra-articular wild-type A2M, CYT-108 A2M, or CYT-98 A2M variants.
Published preclinical study of targeted A2M variants in rat osteoarthritis model.
A2M variants inhibited cartilage catabolism in explants and reduced inflammation and cartilage damage in vivo; CYT-108 showed less cartilage damage than wild-type A2M and CYT-98.
APIC-CF Therapy
undiscloseddrug program · high · Fri May 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Treat mild to moderate osteoarthritis of the knee by concentrating alpha-2-macroglobulin from a patient's blood and injecting it into the painful knee to inhibit cartilage-degrading proteases.
Autologous blood-processing device removes cells and concentrates alpha-2-macroglobulin for intra-articular knee injection.
Clinical trial listed for APIC-CF therapy in mild to moderate knee osteoarthritis.
APIC-PRP
undiscloseddrug program · medium · Wed Oct 01 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Improve healing of non-healing diabetic foot ulcers when added to physician-selected standard of care.
Randomized comparison of standard of care versus APIC-PRP plus standard of care; APIC-PRP is described as platelet-rich plasma with high platelet levels that produce wound-healing growth factors.
Clinical trial listed for safety and efficacy in non-healing diabetic foot ulcers.
Serum and Synovium Protease Inhibitor Levels in Osteoarthritic Joints
exploratoryresearch program · medium
Measure and correlate alpha-2-macroglobulin levels in plasma and knee joints between primary osteoarthritis and post-traumatic/secondary osteoarthritis groups.
Clinical observational study measuring A2M and related protease inhibitor levels in serum and synovial samples from osteoarthritic joints.
Clinical trial record for measuring protease inhibitor levels in primary and secondary osteoarthritic joints.
